1,2-Addition of Alkyl- and Alkenylzirconocene Chlorides to Aldehydes Accelerated by Catalytic Amounts of ZnBr2 as a Method of Synthesizing Secondary Alcohols, Secondary Allylic Alcohols, and in-Situ Oppenauer-Type Oxidation of the Alcohols to Ketones
The present invention relates to pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, including, as an active ingredient, a prostaglandin analog or a pharmaceutically acceptable salt thereof, wherein the compound has excellent effects in inducing Nurr1, and thus, can be useful as a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, in particular, cancer, autoimmune disease such as rheumatoid arthritis, schizophrenia, manic depression and neurodegenerative disease such as Alzheimers disease or Parkinson's disease.
1,2-Addition of Alkyl- and Alkenylzirconocene Chlorides to Aldehydes Accelerated by Catalytic Amounts of ZnBr2 as a Method of Synthesizing Secondary Alcohols, Secondary Allylic Alcohols, and in-Situ Oppenauer-Type Oxidation of the Alcohols to Ketones